Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Wenquan Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7603-3437; OpenAlex author ID A5051338992. Sources: OpenAlex.

Their work

Papers
38 (first author 4, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
117
Papers, trials and grants by year

2015: 2 papers · 2016: 1 paper · 2017: none · 2018: 2 papers · 2019: 4 papers · 2020: 6 papers · 2021: 3 papers · 2022: 5 papers · 2023: 3 papers · 2024: 7 papers · 2025: 2 papers · 2026: 3 papers

Papers 38

  1. DDR1 sustains ferroptosis resistance in pancreatic ductal adenocarcinoma via SLC40A1-mediated iron homeostasis. Co-author DOI 10.1038/s41388-026-03980-w↗
  2. Supervising the recurrence of pancreatic ductal adenocarcinoma using CtDNA-based MIR129-2 methylation detection. Co-author DOI 10.1097/js9.0000000000003449↗
  3. [Corrigendum] RIPK4/PEBP1 axis promotes pancreatic cancer cell migration and invasion by activating RAF1/MEK/ERK signaling. Co-author DOI 10.3892/ijo.2025.5822↗
  4. Tumor-associated macrophages (TAMs): Constructing an immunosuppressive microenvironment bridge for pancreatic ductal adenocarcinoma (PDAC). Co-author DOI 10.1016/j.cpt.2024.07.004↗
  5. Intratumoral IL-33 + CD4 + FoxP3 + regulatory T cell infiltration determines poor clinical outcomes and intensive immunoevasive contexture in patients with pan… Co-author DOI 10.1097/js9.0000000000002733↗
  6. First reported advanced pancreatic cancer with hyperprogression treated with PD-1 blockade combined with chemotherapy: a case report and literature review. Last author DOI 10.1007/s12672-024-01420-3↗
  7. Identification of methylation driver genes for predicting the prognosis of pancreatic cancer patients based on whole-genome DNA methylation sequencing technolo… Co-author DOI 10.1016/j.heliyon.2024.e29914↗
  8. Construction of S100 family members prognosis prediction model and analysis of immune microenvironment landscape at single-cell level in pancreatic adenocarcin… Co-author DOI 10.1097/js9.0000000000001293↗
  9. Pancreatic STAT5 activation promotes Kras G12D-induced and inflammation-induced acinar-to-ductal metaplasia and pancreatic cancer. Co-author DOI 10.1136/gutjnl-2024-332225↗
  10. Deciphering the SOX4/MAPK1 regulatory axis: a phosphoproteomic insight into IQGAP1 phosphorylation and pancreatic Cancer progression. Co-author DOI 10.1186/s12967-024-05377-3↗
  11. Abrogation of KLF5 sensitizes BRCA1-proficient pancreatic cancer to PARP inhibition. Co-author DOI 10.3724/abbs.2023288↗
  12. Efficacy of nab‑paclitaxel vs. Gemcitabine in combination with S‑1 for advanced pancreatic cancer: A multicenter phase II randomized trial. Co-author DOI 10.3892/ol.2024.14293↗
  13. Tumor Microenvironment Responsive CD8+ T Cells and Myeloid-Derived Suppressor Cells to Trigger CD73 Inhibitor AB680-Based Synergistic Therapy for Pancreatic Ca… Co-author DOI 10.1002/advs.202302498↗
  14. Therapeutic advances targeting tumor angiogenesis in pancreatic cancer: Current dilemmas and future directions. Co-author DOI 10.1016/j.bbcan.2023.188958↗
  15. Reshaping the Pancreatic Cancer Microenvironment at Different Stages with Chemotherapy. Last author DOI 10.3390/cancers15092448↗
  16. Neoadjuvant chemotherapy endows CD9 with prognostic value that differs between tumor and stromal areas in patients with pancreatic cancer. Co-author DOI 10.1002/jcla.24517↗
  17. Histone deacetylases: A novel class of therapeutic targets for pancreatic cancer. Co-author DOI 10.1016/j.bbcan.2022.188676↗
  18. A special subtype: Revealing the potential intervention and great value of KRAS wildtype pancreatic cancer. First author DOI 10.1016/j.bbcan.2022.188751↗
  19. Hypoxia-reprogrammed regulatory group 2 innate lymphoid cells promote immunosuppression in pancreatic cancer. Co-author DOI 10.1016/j.ebiom.2022.104016↗
  20. Identification of characteristic markers correlated with Th2 cell infiltration and metabolism molecular subtype in pancreatic adenocarcinoma. Co-author DOI 10.21037/jgo-22-333↗
  21. Human splenic TER cells: A relevant prognostic factor acting via the artemin-GFRα3-ERK pathway in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.33410↗
  22. Bidirectional and dynamic interaction between the microbiota and therapeutic resistance in pancreatic cancer. Co-author DOI 10.1016/j.bbcan.2020.188484↗
  23. Follicular Helper T Cells Remodel the Immune Microenvironment of Pancreatic Cancer via Secreting CXCL13 and IL-21. Co-author DOI 10.3390/cancers13153678↗
  24. Killing the "BAD": Challenges for immunotherapy in pancreatic cancer. First author DOI 10.1016/j.bbcan.2020.188384↗
  25. Cancer-associated fibroblasts in therapeutic resistance of pancreatic cancer: Present situation, predicaments, and perspectives. Co-author DOI 10.1016/j.bbcan.2020.188444↗
  26. Advances on diagnostic biomarkers of pancreatic ductal adenocarcinoma: A systems biology perspective. First author DOI 10.1016/j.csbj.2020.11.018↗
  27. TET1 downregulates epithelial-mesenchymal transition and chemoresistance in PDAC by demethylating CHL1 to inhibit the Hedgehog signaling pathway. Co-author DOI 10.1038/s41388-020-01407-8↗
  28. Chemotherapy-Induced Reduction of Neutrophil-to-Lymphocyte Ratio Is Associated With Better Survival in Pancreatic Adenocarcinoma: A Meta-Analysis. Co-author DOI 10.1177/1073274820977135↗
  29. Molecular drivers and cells of origin in pancreatic ductal adenocarcinoma and pancreatic neuroendocrine carcinoma. First author DOI 10.1186/s40164-020-00184-0↗
  30. Prognostic value of γ-glutamyltransferase-to-albumin ratio in patients with pancreatic ductal adenocarcinoma following radical surgery. Co-author DOI 10.1002/cam4.1957↗
  31. Research progress and design optimization of CAR-T therapy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cam4.2430↗
  32. Tumor-Infiltrating NETs Predict Postsurgical Survival in Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-018-6941-4↗
  33. The systemic inflammation response index predicts survival and recurrence in patients with resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.2147/cmar.s197911↗
  34. A novel scoring system predicts postsurgical survival and adjuvant chemotherapeutic benefits in patients with pancreatic adenocarcinoma: Implications for AJCC-… Co-author DOI 10.1016/j.surg.2018.01.017↗
  35. Tumor-Infiltrating Platelets Predict Postsurgical Survival in Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-018-6727-8↗
  36. ALDOA functions as an oncogene in the highly metastatic pancreatic cancer. Co-author DOI 10.1016/j.canlet.2016.01.054↗
  37. A preoperative serum signature of CEA+/CA125+/CA19-9 ≥ 1000 U/mL indicates poor outcome to pancreatectomy for pancreatic cancer. Co-author DOI 10.1002/ijc.29242↗
  38. Metabolic tumor burden: a new promising way to reach precise personalized therapy in PDAC. Co-author DOI 10.1016/j.canlet.2015.01.023↗

Closest collaborators

The 25 strongest of 117 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Liang Liu · 20 shared papers, 2015–2026 · strength 3.21
  2. Xianjun Yu · 20 shared papers, 2015–2026 · strength 2.23
  3. Huaxiang Xu · 19 shared papers, 2015–2026 · strength 2.14
  4. Heli Gao · 14 shared papers, 2018–2022 · strength 1.51
  5. Chuntao Wu · 13 shared papers, 2015–2026 · strength 1.18
  6. Tianjiao Li · 9 shared papers, 2019–2022 · strength 1.00
  7. Wuhu Zhang · 9 shared papers, 2019–2022 · strength 0.94
  8. Liang Liu · 7 shared papers, 2019–2026 · strength 0.85
  9. Ning Pu · 4 shared papers, 2023–2026 · strength 0.85
  10. Shuo Li · 8 shared papers, 2018–2021 · strength 0.71
  11. Xuan Han · 6 shared papers, 2020–2022 · strength 0.70
  12. Taochen He · 3 shared papers, 2025–2026 · strength 0.68
  13. Zhihang Xu · 3 shared papers, 2022–2026 · strength 0.67
  14. Zijin Xu · 3 shared papers, 2022–2024 · strength 0.65
  15. Wenhui Lou · 3 shared papers, 2023–2026 · strength 0.59
  16. Liang Liu · 3 shared papers, 2023–2024 · strength 0.57
  17. Jinbin Jia · 2 shared papers, 2024–2025 · strength 0.56
  18. Jianang Li · 2 shared papers, 2024–2025 · strength 0.53
  19. Wenchuan Wu · 3 shared papers, 2023–2025 · strength 0.52
  20. Quanxing Ni · 8 shared papers, 2015–2019 · strength 0.52
  21. Zheng Zhang · 2 shared papers, 2023–2024 · strength 0.47
  22. Maozhen Peng · 2 shared papers, 2023–2024 · strength 0.45
  23. Yanfei An · 2 shared papers, 2023–2025 · strength 0.44
  24. Wenhui Lou · 2 shared papers, 2022–2024 · strength 0.43
  25. Yun Jin · 2 shared papers, 2024–2025 · strength 0.43

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.